Oncology | Urothelial Cancer

It’s time for new molecular insights in bladder cancer

Urothelial cancer in the US

Urothelial cancer is the fifth most common cancer in the US accounting 3.5% of new cancer cases in 2020 (1). It is more common in men than women, and predominantly affects older people, with an average age at diagnosis of 73 years.

Doctor talking with patient
FGFR alterations in urothelial cancer

Fibroblast growth factor receptors (FGFRs) are membrane-bound receptor tyrosine kinases that initiate intracellular signaling pathways involved in proliferation, differentiation, migration and angiogenesis. Activating alterations within the FGFR genes have been found in a subset of urothelial cancer patients (2, 3), demonstrating the importance of this type of genetic defect as a driver of tumor development and progression.

Reliably detect actionable genetic alterations

The therascreen FGFR RGQ RT-PCR Kit version 2 is a unique molecular test to identify actionable genetic alterations in patients with urothelial cancer, who may be eligible for treatment with BALVERSA (erdafitinib), an FGFR inhibitor drug.

Find a lab offering the test.

Female doctor discussing results with patient
grandfather and grandson playing together
Give your oncologists results they can trust

The therascreen FGFR RGQ RT-PCR Kit is the first FDA-approved companion diagnostic (CDx) test to detects two point mutations in exon 7 [p.R248C (c.742C>T) and p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene in RNA samples derived from clinical formalin-fixed paraffin-embedded (FFPE) UC tissue.

Contact an expert
Discover how FGFR testing can help you and your patients.
Enabling precision healthcare for your patients
Enabling precision healthcare for your patients
Our therascreen kits for solid tumor diagnostics allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.
A woman in protective goggles holding a tablet in a lab
Get the latest insights from oncology experts
Catch up with our solid tumor webinars wherever you are, at a time that works for you.